Recent Advances in Serum Biomarkers for Risk Stratification and Patient Management in Cardio-Oncology

Overview

Journal Curr Cardiol Rep

Publisher Current Science

Specialty Cardiology & Vascular Diseases

Date 2023 Feb 15

PMID 36790618

Authors

Pouya Joolharzadeh

Mario Rodriguez

Raja Zaghlol

Lauren N Pedersen

Jesus Jimenez

Carmen Bergom

Joshua D Mitchell

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: Following significant advancements in cancer therapeutics and survival, the risk of cancer therapy-related cardiotoxicity (CTRC) is increasingly recognized. With ongoing efforts to reduce cardiovascular morbidity and mortality in cancer patients and survivors, cardiac biomarkers have been studied for both risk stratification and monitoring during and after therapy to detect subclinical disease. This article will review the utility for biomarker use throughout the cancer care continuum.

Recent Findings: A recent meta-analysis shows utility for troponin in monitoring patients at risk for CTRC during cancer therapy. The role for natriuretic peptides is less clear but may be useful in patients receiving proteasome inhibitors. Early studies explore use of myeloperoxidase, growth differentiation factor 15, galectin 3, micro-RNA, and others as novel biomarkers in CTRC. Biomarkers have potential to identify subclinical CTRC and may reveal opportunities for early intervention. Further research is needed to elucidate optimal biomarkers and surveillance strategies.

Citing Articles

Cardiotoxicity following thoracic radiotherapy for lung cancer.

Walls G, Bergom C, Mitchell J, Rentschler S, Hugo G, Samson P Br J Cancer. 2024; 132(4):311-325.

PMID: 39506136 PMC: 11833127. DOI: 10.1038/s41416-024-02888-0.

Life expectancy in cancer patients with pulmonary thromboembolism: From clinical prognostic biomarkers and paraclinical investigations to therapeutic approaches (Review).

Nemtut D, Petreanu C, Ulmeanu R, Rajnoveanu A, Rajnoveanu R Exp Ther Med. 2024; 28(3):354.

PMID: 39071911 PMC: 11273361. DOI: 10.3892/etm.2024.12643.

Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review.

Mandala E, Lafara K, Kokkinovasilis D, Kalafatis I, Koukoulitsa V, Katodritou E Life (Basel). 2024; 14(4).

PMID: 38672794 PMC: 11050930. DOI: 10.3390/life14040524.

Recent Advances in Serum Biomarkers for Cardiological Risk Stratification and Insight into the Cardiac Management of the Patients With Hematological Malignancies Treated With Targeted Therapy.

Andreescu M Cureus. 2023; 15(11):e49696.

PMID: 38033434 PMC: 10688222. DOI: 10.7759/cureus.49696.

Anthracycline's Effects on Heart Rate Variability in Children with Acute Lymphoblastic Leukemia: Early Toxicity Signs-Pilot Study.

Lazar D, Cainap S, Maniu D, Blag C, Bota M, Lazar F J Clin Med. 2023; 12(22).

PMID: 38002666 PMC: 10672281. DOI: 10.3390/jcm12227052.

References

Januzzi Jr J, Mahler S, Christenson R, Rymer J, Newby L, Body R . Recommendations for Institutions Transitioning to High-Sensitivity Troponin Testing: JACC Scientific Expert Panel. J Am Coll Cardiol. 2019; 73(9):1059-1077. DOI: 10.1016/j.jacc.2018.12.046. View

Januzzi Jr J, Peacock W, Maisel A, Chae C, Jesse R, Baggish A . Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007; 50(7):607-13. DOI: 10.1016/j.jacc.2007.05.014. View

Lenderink T, Heeschen C, Fichtlscherer S, Dimmeler S, Hamm C, Zeiher A . Elevated placental growth factor levels are associated with adverse outcomes at four-year follow-up in patients with acute coronary syndromes. J Am Coll Cardiol. 2006; 47(2):307-11. DOI: 10.1016/j.jacc.2005.08.063. View

Okamoto R, Ali Y, Hashizume R, Suzuki N, Ito M . BNP as a Major Player in the Heart-Kidney Connection. Int J Mol Sci. 2019; 20(14). PMC: 6678680. DOI: 10.3390/ijms20143581. View

Xu X, Nie Y, Wang F, Bai Y, Lv Z, Zhang Y . Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation. J Biol Chem. 2014; 289(14):10084-94. PMC: 3974979. DOI: 10.1074/jbc.M113.516278. View

Cornell R, Ky B, Weiss B, Dahm C, Gupta D, Du L . Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma. J Clin Oncol. 2019; 37(22):1946-1955. PMC: 9798911. DOI: 10.1200/JCO.19.00231. View

Upshaw J . The Role of Biomarkers to Evaluate Cardiotoxicity. Curr Treat Options Oncol. 2020; 21(10):79. DOI: 10.1007/s11864-020-00777-1. View

Mahmood S, Fradley M, Cohen J, Nohria A, Reynolds K, Heinzerling L . Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. J Am Coll Cardiol. 2018; 71(16):1755-1764. PMC: 6196725. DOI: 10.1016/j.jacc.2018.02.037. View

Wechalekar A, Gillmore J, Bird J, Cavenagh J, Hawkins S, Kazmi M . Guidelines on the management of AL amyloidosis. Br J Haematol. 2014; 168(2):186-206. DOI: 10.1111/bjh.13155. View

10.

Russell K, Stern D, Polverini P, Bender J . Neuregulin activation of ErbB receptors in vascular endothelium leads to angiogenesis. Am J Physiol. 1999; 277(6):H2205-11. DOI: 10.1152/ajpheart.1999.277.6.H2205. View

11.

Henri C, Heinonen T, Tardif J . The Role of Biomarkers in Decreasing Risk of Cardiac Toxicity after Cancer Therapy. Biomark Cancer. 2016; 8(Suppl 2):39-45. PMC: 4878717. DOI: 10.4137/BIC.S31798. View

12.

Ky B, Putt M, Sawaya H, French B, Januzzi Jr J, Sebag I . Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2013; 63(8):809-16. PMC: 4286181. DOI: 10.1016/j.jacc.2013.10.061. View

13.

Aula H, Skytta T, Tuohinen S, Luukkaala T, Hamalainen M, Virtanen V . ST2 levels increased and were associated with changes in left ventricular systolic function during a three-year follow-up after adjuvant radiotherapy for breast cancer. Breast. 2019; 49:183-186. PMC: 7375584. DOI: 10.1016/j.breast.2019.12.001. View

14.

Apte R, Chen D, Ferrara N . VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019; 176(6):1248-1264. PMC: 6410740. DOI: 10.1016/j.cell.2019.01.021. View

15.

Accornero F, van Berlo J, Benard M, Lorenz J, Carmeliet P, Molkentin J . Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res. 2011; 109(3):272-80. PMC: 3146170. DOI: 10.1161/CIRCRESAHA.111.240820. View

16.

Pudil R, Mueller C, Celutkiene J, Henriksen P, Lenihan D, Dent S . Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020; 22(11):1966-1983. DOI: 10.1002/ejhf.2017. View

17.

Delombaerde D, Vervloet D, Franssen C, Croes L, Gremonprez F, Prenen H . Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. ESMO Open. 2021; 6(4):100216. PMC: 8287144. DOI: 10.1016/j.esmoop.2021.100216. View

18.

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni C, Veglia F . Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015; 131(22):1981-8. DOI: 10.1161/CIRCULATIONAHA.114.013777. View

19.

Putt M, Hahn V, Januzzi J, Sawaya H, Sebag I, Plana J . Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab. Clin Chem. 2015; 61(9):1164-72. PMC: 4667170. DOI: 10.1373/clinchem.2015.241232. View

20.

Januzzi Jr J, Sakhuja R, ODonoghue M, Baggish A, Anwaruddin S, Chae C . Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department. Arch Intern Med. 2006; 166(3):315-20. DOI: 10.1001/archinte.166.3.315. View